use of Aloevera in liver disease

Evaluation of hepatoprotective activity of Aloevera-A clinical study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/12/002284

Enrollment

100

Registered

2011-12-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- liver disease

Interventions

Intervention1: Aloevera: aloevera was given in dose of 10-30 mg BD to patients with acute liver disease Intervention2: Aloevera: aloevera in dose of 20gm BD orally is given for 6 - 8 weeks along with

Eligibility

Inclusion criteria

Inclusion criteria: patients attending medicine out patient and inpatient department at SVBP hospital,L.L.R.M medical college meerut having liver disease were taken and randomly divided in two groups.

Exclusion criteria

Exclusion criteria: age less than 15yr or more than 60 yr. congenital liver disease pregnant and lactating female chronic decompensated liver disease

Design outcomes

Primary

Measure	Time frame
SGPT SGOT serum bilirubin serum alkaline phosphataseTimepoint: initially after 2 weeks after 4 weeks after 6 weeks after 8 weeks	—

Secondary

Measure	Time frame
NATimepoint: NA	—

Countries

India

Contacts

Public Contactdr kk saxena

L.L.R.M medical college,meerut

drkksaxenamrt@gmail.com9897146248

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026